The Liver Cancer Therapeutics Market was valued at USD 3.12 billion in 2023 and is expected to reach
The liver cancer therapeutics market is expected to drive in upcoming years, which will support the growth of the industry in the long run. According to NCBI, Liver cancer is still one of the most common malignancies in the world, accounting for an estimated 905,677 incident cases and 830,180 deaths globally in 2023 (Global Cancer Observatory). For liver cancer, chronic hepatitis B and C infections as well as alcohol and non-alcoholic fatty liver disease are emerging to be the burden of disease. Liver cancer is the sixth-commonest cancer worldwide. The number of newly diagnosed primary liver cancer cases from 2020-2040 is anticipated to rise sharply; an estimated 1.4 million new diagnoses are projected by 2040.